PR93116

SINGAPORE, Nov. 29, 2021 /PRNewswire=KYODO JBN/ --

- Expanded Facility Provides Comprehensive Capabilities to Support Global

Pharmaceutical Drug Development Programs

Labcorp (http://www.labcorp.com/)(NYSE: LH), a leading global life sciences

company, today announced the expansion of its global offerings and its

footprint in the Asia-Pacific (APAC) region with the opening of a new,

integrated bioanalytical laboratory in Singapore.  

The laboratory features new capabilities that enhance the substantial array of

bioanalytical services currently offered through Labcorp Drug Development

(http://www.drugdevelopment.labcorp.com/), allowing the company to meet

increased demand from pharmaceutical and biotechnology companies.

"Singapore serves as a strategic location from which Labcorp can increase

accessibility by offering regional and international clients comprehensive

support for their bioanalytical studies," said Dr. Paul Kirchgraber, CEO of

Labcorp Drug Development. "With this expansion, the company is advancing its

position as a life science leader in the region and across the globe. The

all-in-one Singapore laboratory offers clients faster turnaround times for data

in early phase trials occurring in the APAC region."

The integrated bioanalytical laboratory will be co-located with Labcorp's

Central Laboratory Services and Clinical Development and Commercialization

Services segments, bolstering the company's laboratory network in APAC. By

expanding its bioanalytical capabilities in Singapore, Labcorp advances its

regulated and non-regulated services and further supports the development of

small and large molecule studies. The new, integrated laboratory will also

offer Good Laboratory Practice (GLP)- and Good Clinical Practice

(GCP)-compliant bioanalysis, liquid chromatography-mass spectrometry and

immunochemistry platforms, as well as clinical biomarker analytical services.

Labcorp hosted an opening ceremony for the laboratory on Wednesday, Nov. 10.

Gan Kim Yong, Singapore's minister for trade and industry, and Dr. Kirchgraber

officiated the opening ceremony. The event also featured a keynote

presentation, a virtual lab tour and scientific sessions from an impressive

line-up of Labcorp Drug Development scientists.

In line with Singapore's plans for Emerging Stronger, this expansion will

strengthen the nation's position as an end-to-end hub for medical technology

product development under the Alliance for Action approach. It will also enable

comprehensive, end-to-end in vitro diagnostic solutions development and

commercialization.

About Labcorp

Labcorp is a leading global life sciences company that provides vital

information to help doctors, hospitals, pharmaceutical companies, researchers,

and patients make clear and confident decisions. Through our unparalleled

diagnostics and drug development capabilities, we provide insights and

accelerate innovations to improve health and improve lives. With more than

70,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE:

LH) reported revenue of $14 billion in FY2020. Learn about Labcorp at

www.labcorp.com, or follow us on LinkedIn

(https://www.linkedin.com/company/labcorp) and Twitter @Labcorp

(https://twitter.com/LabCorp).

SOURCE: Labcorp Drug Development

Image Attachments Links:

   Link: http://asianetnews.net/view-attachment?attach-id=407884